Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 9/20 | 0.49 |
| ▸ | NT5E | P21589 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035770 | 0.89 | FLT3 (0.66) | MKNK1MKNK2FLT3FYNCHEK1 | |
| SCHEMBL3022710 | 0.89 | PIK3CA (0.51) | MKNK1MKNK2FLT3FYNPIK3CA | |
| SCHEMBL3027184 | 0.88 | FYN (0.48) | MKNK1MKNK2FLT3FYNPIK3CA | |
| SCHEMBL3035727 | 0.87 | MKNK1 (0.56) | MKNK1MKNK2FLT3FYN | |
| SCHEMBL3031128 | 0.86 | FYN (0.42) | MKNK1MKNK2FLT3FYNNT5E | |
| SCHEMBL3020669 | 0.85 | FYN (0.46) | MKNK1MKNK2FLT3FYNPIK3CA | |
| SCHEMBL3033524 | 0.84 | FYN (0.45) | FYN | |
| SCHEMBL3025915 | 0.84 | MKNK1 (0.54) | MKNK1MKNK2FLT3FYN | |
| SCHEMBL3022544 | 0.84 | FYN (0.55) | MKNK1MKNK2FLT3FYN | |
| SCHEMBL3029657 | 0.84 | MKNK1 (0.44) | MKNK1MKNK2FLT3FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | claimed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | MKNK1 3849/4885MKNK2 4013/4885FLT3 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.